{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:04Z","timestamp":1786118884723,"version":"build-2736575974"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1097\/med.0b013e32814db831","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T05:17:13Z","timestamp":1209878233000},"page":"213-218","source":"Crossref","is-referenced-by-count":5,"title":["Aldosterone and refractory hypertension"],"prefix":"10.1097","volume":"14","author":[{"given":"Moffat J","family":"Nyirenda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L","family":"Padfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20211004","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1161\/01.HYP.25.3.305","article-title":"Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988\u20131991","volume":"25","author":"Burt","year":"1995","journal-title":"Hypertension"},{"key":"R2-5-20211004","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"R3-5-20211004","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.265.24.3255","article-title":"Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.","volume":"265","year":"1991","journal-title":"JAMA"},{"key":"R4-5-20211004","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"key":"R5-5-20211004","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"R6-5-20211004","first-page":"9","article-title":"1999 World Health Organization: International Society of Hypertension guidelines for the management of hypertension.","volume":"8","author":"Sub-Committee","year":"1999","journal-title":"Blood Press"},{"key":"R7-5-20211004","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"key":"R8-5-20211004","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"R9-5-20211004","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R10-5-20211004","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1097\/01.hjh.0000251894.17132.54","article-title":"Prevalence of the white-coat effect at multiple visits before and during treatment","volume":"24","author":"Verberk","year":"2006","journal-title":"J Hypertens"},{"key":"R11-5-20211004","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3810\/pgm.2000.5.1.1066","article-title":"Contributing factors in resistant hypertension. Truly refractory disease is rarely found in a properly conducted workup","volume":"107","author":"Vidt","year":"2000","journal-title":"Postgrad Med"},{"key":"R12-5-20211004","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11906-006-0085-9","article-title":"Review of resistant hypertension","volume":"8","author":"Ram","year":"2006","journal-title":"Curr Hypertens Rep"},{"key":"R13-5-20211004","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"R14-5-20211004","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1152\/physrev.00030.2003","article-title":"Control of aldosterone secretion: a model for convergence in cellular signaling pathways","volume":"84","author":"Spat","year":"2004","journal-title":"Physiol Rev"},{"key":"R15-5-20211004","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/157340206776877352","article-title":"Aldosterone and the pathogenesis of hypertension","volume":"2","author":"Nyirenda","year":"2006","journal-title":"Curr Hypertens Rev"},{"key":"R16-5-20211004","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev.ph.46.030184.001451","article-title":"Interaction of signals influencing renin release","volume":"46","author":"Gibbons","year":"1984","journal-title":"Annu Rev Physiol"},{"key":"R17-5-20211004","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.HYP.16.4.363","article-title":"Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture","volume":"16","author":"Erdos","year":"1990","journal-title":"Hypertension"},{"key":"R18-5-20211004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2003.10.046","article-title":"Glomerulosa cell: a unique sensor of extracellular K+ concentration","volume":"217","author":"Spat","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"R19-5-20211004","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1210\/endo-85-2-381","article-title":"Effect of (K+) on the secretion of aldosterone","volume":"85","author":"Funder","year":"1969","journal-title":"Endocrinology"},{"key":"R20-5-20211004","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1152\/ajplegacy.1971.220.4.1094","article-title":"Increased adrenocortical potassium in association with increased biosynthesis of aldosterone","volume":"220","author":"Baumber","year":"1971","journal-title":"Am J Physiol"},{"key":"R21-5-20211004","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1210\/endo-103-6-2098","article-title":"Effect of alterations in dietary potassium on the pressor and steroidogenic effects of angiotensins II and III","volume":"103","author":"Campbell","year":"1978","journal-title":"Endocrinology"},{"issue":"3","key":"R22-5-20211004","first-page":"E328","article-title":"Multiplicative interaction between angiotensin II and K concentration in stimulation of aldosterone","volume":"247","author":"Young","year":"1984","journal-title":"Am J Physiol"},{"key":"R23-5-20211004","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/ki.1980.32","article-title":"Escape from the sodium-retaining effects of mineralocorticoids","volume":"17","author":"Knox","year":"1980","journal-title":"Kidney Int"},{"key":"R24-5-20211004","first-page":"3","article-title":"Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome","volume":"45","author":"Conn","year":"1955","journal-title":"J Lab Clin Med"},{"key":"R25-5-20211004","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ncpneph0151","article-title":"Primary aldosteronism: diagnostic and treatment strategies","volume":"2","author":"Mattsson","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"R26-5-20211004","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.tem.2005.02.007","article-title":"Diagnosis of primary aldosteronism: from screening to subtype differentiation","volume":"16","author":"Mulatero","year":"2005","journal-title":"Trends Endocrinol Metab"},{"key":"R27-5-20211004","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1046\/j.1365-2265.2003.01817.x","article-title":"Prevalence and role of a raised aldosterone to renin ratio in the diagnosis of primary aldosteronism: a debate on the scientific logic of the use of the ratio in practice","volume":"59","author":"Padfield","year":"2003","journal-title":"Clin Endocrinol"},{"key":"R28-5-20211004","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0025-6196(12)62114-4","article-title":"Primary aldosteronism: diagnosis and treatment","volume":"65","author":"Young","year":"1990","journal-title":"Mayo Clin Proc"},{"key":"R29-5-20211004","first-page":"459","article-title":"Pseudo-primary aldosteronism, a variant of low-renin essential hypertension?","author":"Baer","year":"1972"},{"key":"R30-5-20211004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(81)90424-4","article-title":"The myth of idiopathic hyperaldosteronism","volume":"2","author":"Padfield","year":"1981","journal-title":"Lancet"},{"key":"R31-5-20211004","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0140-6736(75)91559-7","article-title":"Is low-renin hypertension a stage in the development of essential hypertension or a diagnostic entity?","volume":"1","author":"Padfield","year":"1975","journal-title":"Lancet"},{"key":"R32-5-20211004","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/01.RES.38.6.502","article-title":"Enhanced aldosterone response to angiotensin II in human hypertension","volume":"38","author":"Kisch","year":"1976","journal-title":"Circ Res"},{"key":"R33-5-20211004","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI109065","article-title":"Increased adrenal sensitivity to angiotensin II in low-renin essential hypertension","volume":"61","author":"Wisgerhof","year":"1978","journal-title":"J Clin Invest"},{"key":"R34-5-20211004","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/archinte.1972.03650060041007","article-title":"The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone","volume":"130","author":"Carey","year":"1972","journal-title":"Arch Intern Med"},{"key":"R35-5-20211004","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1530\/eje.0.1510305","article-title":"Would wider screening for primary aldosteronism give any health benefits?","volume":"151","author":"Plouin","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"R36-5-20211004","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.beem.2006.07.008","article-title":"Monogenic mineralocorticoid hypertension","volume":"20","author":"Stowasser","year":"2006","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R37-5-20211004","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"R38-5-20211004","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0272-6386(01)80117-7","article-title":"Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio","volume":"37","author":"Gallay","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"R39-5-20211004","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","article-title":"Low-renin status in therapy-resistant hypertension: a clue to efficient treatment","volume":"22","author":"Eide","year":"2004","journal-title":"J Hypertens"},{"key":"R40-5-20211004","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjhyper.2005.06.031","article-title":"Aldosterone and refractory hypertension: a prospective cohort study","volume":"19","author":"Sartori","year":"2006","journal-title":"Am J Hypertens"},{"key":"R41-5-20211004","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pcad.2006.02.002","article-title":"Use of aldosterone antagonists in resistant hypertension","volume":"48","author":"Calhoun","year":"2006","journal-title":"Prog Cardiovasc Dis"},{"key":"R42-5-20211004","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","article-title":"The role of spironolactone in the treatment of patients with refractory hypertension","volume":"15","author":"Ouzan","year":"2002","journal-title":"Am J Hypertens"},{"key":"R43-5-20211004","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.amjhyper.2005.11.016","article-title":"Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension","volume":"19","author":"Sharabi","year":"2006","journal-title":"Am J Hypertens"},{"key":"R44-5-20211004","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"R45-5-20211004","doi-asserted-by":"crossref","first-page":"558","DOI":"10.7326\/0003-4819-87-5-558","article-title":"Disparate patterns of aldosterone response during diuretic treatment of hypertension","volume":"8","author":"Weber","year":"1977","journal-title":"Ann Intern Med"},{"key":"R46-5-20211004","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","article-title":"Aldosterone blockade: an emerging strategy for abrogating progressive renal disease","volume":"119","author":"Epstein","year":"2006","journal-title":"Am J Med"},{"key":"R47-5-20211004","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"key":"R48-5-20211004","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"R49-5-20211004","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1291\/hypres.29.211","article-title":"Combination therapy with aldosterone blockade and rennin\u2013angiotensin inhibitors confers organ protection","volume":"29","author":"Sato","year":"2006","journal-title":"Hypertens Res"},{"key":"R50-5-20211004","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","article-title":"Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?","volume":"18","author":"Mahmud","year":"2005","journal-title":"Am J Hypertens"},{"key":"R51-5-20211004","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0895-7061(00)01301-7","article-title":"Laragh's lessons in pathophysiology and clinical pearls for treating hypertension","volume":"14","author":"Laragh","year":"2001","journal-title":"Am J Hypertens"}],"container-title":["Current Opinion in Endocrinology, Diabetes & Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01266029-200706000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:01:18Z","timestamp":1786035678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01266029-200706000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/med.0b013e32814db831","relation":{},"ISSN":["1752-296X"],"issn-type":[{"value":"1752-296X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}